Chris
Engineer & Entrepreneur, Equity/Crypto Swing Trader, Macro & Trade Setups
Tempus AI is one of the highest-conviction setups now, and the widespread doubt about its move is itself bullish. The skepticism was earned by a year of false starts, but clearing $58 should flip sentiment quickly, with a near-term target of $68-$73. A weekly break above $73 sets a medium- to long-term target of $144-$168. Momentum is building on both lower and higher timeframes, while about 38M shares, roughly 28% of the float, are sold short into the breakout. x.com x.com x.comÂ
Tempus AI sits at the center of the convergence of AI, healthcare, genomics and data-driven medicine, a powerful long-term theme, and its chart looks close to a major breakout. Price is trying to reclaim the daily cloud and the key 0.5 Fibonacci level while daily RSI shows strong relative strength. A confirmed breakout would open an initial move toward $70, making it a top outperformer pick for the rest of 2026. x.comÂ
Tempus AI is being repriced because its acquisition of Personalis benefits directly from positive Moderna news, while short covering is still underway. Short interest is about 30 million shares, over eight days of normal 3-5 million share volume, and the three-day surge absorbed under a third of it. A small market cap makes the stock easy to push higher, and bullish divergences on the three-day and weekly charts usually last weeks to months. Resistance sits at 74-76, 80 and 84-86. x.com x.com … Show more
Tempus AI's chart points to $90 and then $100 if it clears the $85 call wall. It broke out of a falling wedge after three bottoms near $41.73, is up 58.9% over 30 sessions and is back above the 0.618 Fibonacci level at $80.41. Options are cheap, with implied volatility of 77 against realized volatility of 85. x.comÂ
AI-for-science stocks show a typical pump-and-dump setup driven by Chinese and Hong Kong hedge funds, and more pumps and dumps are likely. These funds trade narratives and price in an extremely bright future, so consensus forms fast and crowded positions reverse easily. When Chinese sell-side analysts or the Chinese community on X are loud about a thesis, it is a trade to avoid. Fundamentals still look exciting, and key moving averages are the signal to re-enter long. x.com x.comÂ
Tempus AI's 31% short interest adds fuel to its Stage 2 breakout. x.comÂ
Tempus AI may be about to go on a run, and its short interest looks a bit rich. As of June 15, 38M of its 180M shares outstanding were sold short, a roughly $2B position at $54. x.comÂ
Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.comÂ
Tempus AI's selloff after it beat and raised guidance looks like a great deal, and a further drop would be a chance to buy more. x.comÂ
Tempus AI's thesis remains intact after objectively strong earnings and a guidance raise. It looks less threatened by Anthropic than other software names because its datasets form its moat, for now. Software multiples remain a big question, and these stocks are struggling to catch a break, but the technical setup still looks good despite the pullback. x.comÂ
Tempus AI may go lower near term because of valuation, leadership reputation and insider selling, despite an amazing business. With about 25% growth expected and profitability uncertain, it is not obviously cheap. Glassdoor reviews matter in medicine's high-trust setting, and ongoing insider sales echo founder patterns that ended badly. The data piece, about 5% of market cap, can earn a high multiple, so the stock looks reasonably priced if adoption continues. x.comÂ
AI biotech names such as Tempus AI, Recursion, Ginkgo Bioworks and Prime Medicine could become the new home for money rotating out of AI and semiconductor leaders, with Moderna and Merck's positive phase 3 melanoma results for their mRNA neoantigen therapy a possible catalyst. Sentiment toward AI in healthcare should be far warmer than toward job-displacing AI, since everyone faces disease, and could top the semis trade. Indices could chop or fall while these biotechs outperform. x.com x.com … Show more
